Key Highlights

  • Acurx Pharmaceuticals shares closed down 12% at $1.46.
  • The company received conditional FDA acceptance for CIFBEZY as the Brand name for ibezapolstat.
  • The milestone was accompanied by a USPTO Trademark allowance.
  • The company is advancing its lead CDI antibiotic toward an international Phase 3 registration trial and subsequent NDA filing.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) shares closed down 12% at $1.46 despite the company receiving conditional FDA acceptance for CIFBEZY as the brand name for ibezapolstat, alongside a USPTO trademark allowance.

What Happened

The regulatory milestones bolster commercial-readiness efforts as the company advances its lead CDI antibiotic toward an international Phase 3 registration trial and subsequent NDA filing.

Market Reaction

Shares fell despite the constructive regulatory news, a decline that stands in contrast to the generally positive framing of brand name acceptance and trademark milestones as steps toward commercialization readiness.

Outlook

Progress toward the international Phase 3 registration trial for ibezapolstat, and the subsequent NDA filing, represents the next major disclosed milestones for Acurx Pharmaceuticals.